Stockchase Research Editor: Michael O'Reilly With net sales up almost 15% over the year, this iconic global brand is a TOP PICK. Recently reported earnings beat expectations by over 25% and support a stellar 40% ROE. It trades at 12x earnings, compared to peers at 30x. Management guidance remains online and projects growth continuing through the balance of the year. We recommend a stop loss at $13, looking to achieve $27 -- upside potential over 55%. Yield 2.4% (Analysts’ price target is $27.09)
(A Top Pick Jul 12/22, Down 2.1%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with LEVI is progressing well. We now recommend to trail up the stop from $13 to $15.
(A Top Pick Jul 12/22, Down 11.6%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with LEVI has triggered its stop at $15. To remain disciplined, we recommend covering the position at this time.
Today, it reported an earnings and sales beat, but shares fell 16%. They lowered their full-year gross margin outlook a lot, but didn't touch earnings guidance. Also, they forecast a sales decline around 8-12% this quarter.
Could benefit from the weight-loss drug boom, because those who take those drugs will need need jeans. But the company reported a weak quarter and cut guidance.
They just reported a minor sales miss but an earnings beat and cut their full-year revenue forecast though asserted their earnings would meet the midpoint of previous guidance. Europe and direct-to-consumer are strong, but Asian and America are weaker.
It reported after the bell superb 12% YOY sales growth, strength in the Americas, Europe and direct to consumer channels. They beat gross margins, but due to higher expenses, they delivered a modest earnings beat. Their full-year forecast was a little mixed, but overall good.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.
They report Monday. The last quarter when they offered guidance, the stock got hammered. Apparel has been a mixed bag.